Provided by Tiger Trade Technology Pte. Ltd.

Alaunos Therapeutics

0.8381
+0.095612.88%
Post-market: 0.8199-0.0182-2.17%19:53 EDT
Volume:311.74K
Turnover:257.63K
Market Cap:2.45M
PE:-0.47
High:0.8896
Open:0.7400
Low:0.7201
Close:0.7425
52wk High:4.59
52wk Low:0.7190
Shares:2.92M
Float Shares:2.06M
Volume Ratio:3.27
T/O Rate:15.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7684
EPS(LYR):-2.1977
ROE:-185.95%
ROA:-81.13%
PB:3.75
PE(LYR):-0.38

Loading ...

Alaunos Therapeutics Announces New Registered Direct Offering

TIPRANKS
·
Sep 23

Alaunos Therapeutics Prices Registered Direct Offering at USD 1.46 Per Share for USD 1.12 Million Gross Proceeds

Reuters
·
Sep 18

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

THOMSON REUTERS
·
Sep 18

Alaunos Therapeutics Cuts Stockholder Meeting Quorum Requirement to One-Third from Majority

Reuters
·
Sep 17

Alaunos Net Loss Narrows to $1.9 Million in Q2 2026; Revenue Posts no Revenue in H1 2026

Reuters
·
Aug 15

Alaunos Reports New Preclinical Analysis Showing Aln1003 Lowers Liver Weight in 48-day DIO Mouse Study

Reuters
·
Jun 29

Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies

TIPRANKS
·
May 27

Alaunos publishes investor presentation on ALN1003 preclinical data

Reuters
·
May 26

Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies

TIPRANKS
·
May 18

Alaunos reports preclinical ALN1003 data in obesity mouse studies showing improved insulin markers

Reuters
·
May 18

Alaunos Therapeutics Inc - Aln1003-Treated Animals Had Significantly Lower Homa-Ir Scores After Body Fat Adjustment

THOMSON REUTERS
·
May 18

Alaunos Reports Preclinical Aln1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

THOMSON REUTERS
·
May 18

Alaunos Therapeutics Inc - Cash Runway Extends Into Q2 2026

THOMSON REUTERS
·
May 18

Alaunos net loss widens to $1 million in Q1 FY26

Reuters
·
May 16

Valion Bio appoints Melinda Lackey general counsel, SVP legal affairs

Reuters
·
May 05

Press Release: Valion Bio Appoints Melinda Lackey as General Counsel

Dow Jones
·
May 05

Alaunos Therapeutics Faces Nasdaq Non-Compliance, Delisting Risk

TIPRANKS
·
Apr 16

Alaunos Therapeutics flags Nasdaq noncompliance after stockholders’ equity falls below 2,500,000

Reuters
·
Apr 16

Alaunos FY25 net loss narrows 10.8% to $4.2 million

Reuters
·
Apr 01